Erlotinib Completed Phase 2 Trials for Recurrent Non-Small Cell Lung Carcinoma / Adenosquamous Lung Carcinoma / Large Cell Lung Carcinoma / Adenocarcinoma of the Lung / Squamous Cell Lung Carcinoma / Bronchioloalveolar Carcinoma Treatment

IndicationsStatusPurposePhase
CompletedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT01294306MK2206 and Erlotinib Hydrochloride in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Have Progressed After Previous Response to Erlotinib Hydrochloride Therapy